Lipid Metabolic Status in Thyroid Carcinoma (LITCA)

This study has been completed.
Sponsor:
Collaborator:
Iuliu Hatieganu University of Medicine and Pharmacy
Information provided by (Responsible Party):
PICIU DOINA, Prof. Dr. I. Chiricuta Institute of Oncology
ClinicalTrials.gov Identifier:
NCT01487057
First received: December 5, 2011
Last updated: December 26, 2012
Last verified: December 2012
  Purpose

The continuous increase of the incidence of the thyroid cancer in the last years has taken this neoplasia among the first 4 frequent cancers in the cancer registry of the Institute of Oncology "Prof.Ion Chiricuţă" from Cluj-Napoca (IOCN), with a total number of over 470 new cases per year, added to the other 3700 cases already being in the evidence of the Institute.

The radical treatment brings for a long term a compensated chronic drug induces mYxoedema with it's important side effects. Among these one can find the dislipidemia and the change of the high sensitive C reactive protein (hsCRP) serological value. In the last years, many epidemiological studies have confirmed the fact that the patients with a high serological value of the hsCRP present a higher risk for the coronary disease and heart attack.

Prospective studies developed in european countries and in USA have provided results that are related to the predictive value of the hsCRP determinations over the cardiovascular risk. Thus, hsCRP is an indirect risk factor for the coronary disease. The risk for cardiovascular disease is 2 to 7 times higher at the people with a high level of hsCRP comparing to ones with low levels; the increase of the hsCRP serological value can be determined several years before the clinical debut of the coronary disease.

The screening for this population group with a high risk can introduce in use the prevention of the cardiac pathology and change the approach to the monitoring of the patients with thyroid cancer. A selection protocol will be elaborated for the patients that will withdraw the hormone treatment by using recombinant thyroid stimulating hormone (TSH) or will have personalised monitoring algorithm, with a shortening of the hormone treatment withdrawal.


Condition
Thyroid Carcinoma
Dyslipidemias
Risk Reduction Behavior
Hormone Replacement

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: "Evaluation of Lipid Metabolic Status and of Cardiovascular Risk at Patients With Thyroid Carcinoma, Radically Treated and With Chronic Thyroid Hormonal Substitution"

Resource links provided by NLM:


Further study details as provided by Prof. Dr. I. Chiricuta Institute of Oncology:

Primary Outcome Measures:
  • hsCRP an inflammatory biomarker for cardiovascular risk [ Time Frame: May 2012 ] [ Designated as safety issue: No ]
    hsCRP in thyroid hormone withdrwal for patients with thyroid carcinoma radically treated


Secondary Outcome Measures:
  • hsCRP may increase in repeated thyroid hormone withdrawal [ Time Frame: May 2012 ] [ Designated as safety issue: No ]

Other Outcome Measures:
  • hsCRP related to thyroid hormone withdrawal in patients with thyroid carcinoma radically treated [ Time Frame: May 2012 ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: February 2011
Study Completion Date: May 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Thyroid cancer, lipids, LT4 withdrawal
Thyroid cancer, Lipids, LT4 substitution

Detailed Description:

Although considered a rare type of cancer with an incidence under 6 cases for 100 000 persons, the thyroid carcinoma is the most frequent endocrine tumor. The incidence of this malignant disease has exponentially increased in the last decade, so that many specially centers in the world have focused on a better strategy of diagnosis, of treatment and of monitoring. By applying a suitable multimodal treatment, the prognosis of this disease is excellent, offering the patients a survival rate of over 90% at 10 years. During the monitoring of the disease, the patients are periodically supposed to withdraw the hormone treatment; because of this hormone imbalance, there will be important changes of the metabolism, especially the lipid one. This is the reason why we are preoccupied to increase the quality of life of the patients addicted to a chronic thyroid hormone therapy. The aim of this study is to demonstrate the way in which the lipid profile is influenced and to quantify the cardiovascular risk for the patients radically treated of thyroid cancer, by total thyroidectomy, metabolic irradiation and undergoing a chronic thyroid hormone treatment. Nowadays, Romania is one of the countries in which these patients are supposed to be kept in a iatrogenous myxoedema, the alternative being the recombinant thyroid stimulating hormone. For the patients with the mentioned diagnosis, the lipid profile will be determined and will consist of the following: total serologic cholesterol, cholesterol fractions, triglycerides and C reactive protein highly sensitive (hsCRP). A score for the cardiovascular accident risk will be elaborated. The attempt of classifying in cardiovascular risk groups the patients through the present study, would facilitate the selection of the patients and their access to therapies and modern monitoring strategies.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

We will prospectively study a group of patients from the evidence of IOCN, with the histology of differentiated thyroid cancer, radically treated with total thyroidectomy, radioiodine therapy and undergoing chronic substitutive hormone treatment, levothyroxine. The evaluation of these patients will be done during the routine oncological control, after 6-12 months post therapy, while withdrawing the hormone treatment and inducing a short-term iatrogenic myxedema. We are estimating a total number of 30 patients with 3 successive determinations in 1 year. The ethics committee will evaluate this study and each patient will be included voluntarily, following clear information of the patient and an informed consent.

Criteria

Inclusion Criteria:

  • thyroid carcinoma radically treated (surgery, radioiodine, thyroid hormone suppression )

Exclusion Criteria:

  • other causes of high CRP (infection, inflammation)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01487057

Locations
Romania
Institute of Oncology "Prof.dr.I.Chiricuta"
Cluj-Napoca, Cluj, Romania, 400015
Sponsors and Collaborators
Prof. Dr. I. Chiricuta Institute of Oncology
Iuliu Hatieganu University of Medicine and Pharmacy
Investigators
Study Director: Alexandru Irimie, PhD IOCN
  More Information

Additional Information:
No publications provided

Responsible Party: PICIU DOINA, MD, PhD, Prof. Dr. I. Chiricuta Institute of Oncology
ClinicalTrials.gov Identifier: NCT01487057     History of Changes
Other Study ID Numbers: ChiricutaIO
Study First Received: December 5, 2011
Last Updated: December 26, 2012
Health Authority: Romania: Ethics Committee

Keywords provided by Prof. Dr. I. Chiricuta Institute of Oncology:
thyroid cancer
dislipidemia
cardiovascular risk

Additional relevant MeSH terms:
Thyroid Diseases
Dyslipidemias
Carcinoma
Thyroid Neoplasms
Endocrine System Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Head and Neck Neoplasms

ClinicalTrials.gov processed this record on October 19, 2014